RhoA/ROCK Pathway is the Major Molecular Determinant of Basal Tone in Intact Human Internal Anal Sphincter

Satish Rattan  
*Thomas Jefferson University*, Satish.Rattan@jefferson.edu

Jagmohan Singh  
*Thomas Jefferson University*

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/gastro_hepfp](http://jdc.jefferson.edu/gastro_hepfp)

Part of the [Gastroenterology Commons](http://jdc.jefferson.edu/gastrohepfp), and the [Hepatology Commons](http://jdc.jefferson.edu/gastrohepfp)

Recommended Citation

Rattan, Satish and Singh, Jagmohan, "RhoA/ROCK Pathway is the Major Molecular Determinant of Basal Tone in Intact Human Internal Anal Sphincter" (2012). Division of Gastroenterology and Hepatology Faculty Papers. Paper 9.  
[http://jdc.jefferson.edu/gastro_hepfp/9](http://jdc.jefferson.edu/gastro_hepfp/9)
RhoA/ROCK Pathway is the Major Molecular Determinant of Basal Tone in Intact Human Internal Anal Sphincter
Satish Rattan and Jagmohan Singh
Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

**Backgrounds & Aims**
Knowledge of molecular control mechanisms underlying the basal tone in the intact human IAS is critical for the pathophysiology and rational therapy for debilitating rectoanalis motility disorders.

**Methods**
We determined the effects of ROCK and PKC-selective inhibitors Y 27632 and Gö 6850 (10−8 to 10−4 M), respectively on the basal tone in the IAS vs. the RSM. We performed Western blot analysis, confocal microscopy and enzymatic activity assay to determine the levels, membrane distribution and enzyme activity of RhoA/ROCKII, PKcs, MYPT1, CPI-17, and MLCP2 before and after Y 27632 and Gö 6850.

**Results**

**Conclusions**
• RhoA/ROCK are constitutively active in the IAS, and this pathway (in contrast with PKC) is the critical determinant of the basal tone in the human IAS.
• Therefore, RhoA/ROCK are novel therapeutic targets for a number of rectoanal motility disorders in humans.